Orchestra BioMed Holdings Inc. - Asset Resilience Ratio
Orchestra BioMed Holdings Inc. (OBIO) has an Asset Resilience Ratio of 77.35% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Orchestra BioMed Holdings Inc. short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Orchestra BioMed Holdings Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Orchestra BioMed Holdings Inc. balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Orchestra BioMed Holdings Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore OBIO long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $89.49 Million | 77.35% |
| Total Liquid Assets | $89.49 Million | 77.35% |
Asset Resilience Insights
- Very High Liquidity: Orchestra BioMed Holdings Inc. maintains exceptional liquid asset reserves at 77.35% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Orchestra BioMed Holdings Inc. Industry Peers by Asset Resilience Ratio
Compare Orchestra BioMed Holdings Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Enliven Therapeutics Inc.
NASDAQ:ELVN |
Biotechnology | 83.46% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.12% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
Annual Asset Resilience Ratio for Orchestra BioMed Holdings Inc. (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Orchestra BioMed Holdings Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 62.53% | $71.82 Million | $114.86 Million | +4.05pp |
| 2024-12-31 | 58.49% | $44.55 Million | $76.17 Million | -1.42pp |
| 2023-12-31 | 59.90% | $57.04 Million | $95.21 Million | -7.06pp |
| 2022-12-31 | 66.97% | $64.00 Million | $95.57 Million | +59.88pp |
| 2021-12-31 | 7.08% | $958.00K | $13.53 Million | -33.47pp |
| 2020-12-31 | 40.55% | $15.45 Million | $38.09 Million | -- |
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develop… Read more